Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,521 JPY | +0.70% | -2.66% | -9.79% |
Sales 2024 | 1,604B 10.25B 855B | Sales 2025 * | 1,656B 10.58B 883B | Capitalization | 2,708B 17.31B 1,445B |
---|---|---|---|---|---|
Net income 2024 | 17.04B 109M 9.09B | Net income 2025 * | 94.35B 603M 50.33B | EV / Sales 2024 | 1.84 x |
Net Debt 2024 * | 503B 3.22B 269B | Net Debt 2025 * | 512B 3.27B 273B | EV / Sales 2025 * | 1.94 x |
P/E ratio 2024 |
173
x | P/E ratio 2025 * |
28.8
x | Employees | 14,484 |
Yield 2024 |
4.26% | Yield 2025 * |
4.98% | Free-Float | 98.83% |
Latest transcript on Astellas Pharma Inc.
1 day | +0.70% | ||
1 week | -2.66% | ||
Current month | +0.46% | ||
1 month | +5.19% | ||
3 months | -8.70% | ||
6 months | -13.36% | ||
Current year | -9.79% |
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 01/86/01 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | 01/11 |
Kenji Yasukawa
CHM | Chairman | 63 | 01/86/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 63 | 01/86/01 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 01/86/01 |
Tatsuro Ishizuka
BRD | Director/Board Member | 68 | 01/19/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.47% | 19 M€ | +11.67% | ||
2.09% | 240 M€ | +15.33% | ||
2.01% | 60 M€ | +20.57% | ||
1.99% | 10 M€ | +13.46% | - |
Date | Price | Change | Volume |
---|---|---|---|
14/24/14 | 1,521 | +0.70% | 6 123 400 |
13/24/13 | 1,510 | -1.11% | 4,597,000 |
10/24/10 | 1,528 | -0.88% | 6,638,000 |
09/24/09 | 1,541 | -0.23% | 5,938,700 |
08/24/08 | 1,544 | -1.15% | 7,330,800 |
Delayed Quote Japan Exchange, May 14, 2024 at 11:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.79% | 17.34B | |
+29.98% | 682B | |
+31.86% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+4.07% | 285B | |
+16.21% | 240B | |
+9.49% | 209B | |
-8.63% | 203B | |
+7.09% | 165B |
- Stock Market
- Equities
- 4503 Stock